Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2022
This article has no abstract
Epistemonikos ID: 296c9931f43e2101304b1ae684ebadddf756c7a4
First added on: Apr 11, 2025